Navigation Links
Par Pharmaceutical Reports Third Quarter 2008 Results
Date:11/6/2008

7) (330) (335)

Loss on marketable

securities and other

investments, net (2,507) - (2,940) (4,643)

Interest income 2,285 3,680 7,428 10,265

Interest expense (1,667) (1,691) (5,001) (5,136)

Income (loss) from

continuing operations

before provision

for income taxes 2,733 1,952 (20,617) 70,122

Provision (benefit)

for income taxes 923 683 (5,158) 24,541

Income (loss) from

continuing operations 1,810 1,269 (15,459) 45,581

Discontinued operations:

Gain from discontinued

operations - - 505 -

Provision for

income taxes 150 - 863 -

Loss from discontinued

operations 150 - 358 -

Net income (loss) $1,660 $1,269 ($15,817) $45,581

Basic earnings

(loss) per share

of common stock:

Income (loss) from

continuing operations $0.05 $0.04 ($0.46) $1.31

Loss from discontinued

operations (0.00) - ($0.01) -

Net income (loss) $0.05 $0.04 ($0.47) $1.31

Diluted earnings

(loss) per share

of common stock:

Income (loss) from

continuing operations $0.05 $0.04 ($0.46) $1.30

Loss from discontinued

operations (0.00) - (0.01) -

Net income (loss) $0.05 $0.04 ($0.47) $1.30

Weighted average

number of common

shares outstanding:

Basic 33,322 34,738 33,282 34,677

Diluted 33,366 34,906 33,28
'/>"/>

SOURCE Par Pharmaceutical Companies, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine news :

1. Tianyin Pharmaceutical Co., Inc. to Host Fiscal Year 2009 First Quarter Earnings Conference Call on Tuesday, November 11, 2008 at 8:30 a.m. EST
2. Webcast Alert: Isis Pharmaceuticals Cardiovascular Program Review
3. Caraco Pharmaceutical Laboratories, Ltd. to Market Generic Sinemet(R) Tablets
4. Alseres Pharmaceuticals, Inc. to Present at Rodman & Renshaw 10th Annual Healthcare Conference
5. Lotus Pharmaceuticals to Present at Rodman & Renshaw Conference
6. Jazz Pharmaceuticals to Present at Investor Conferences
7. Rib-X Pharmaceuticals, Inc. to Present at the Rodman & Renshaw 10th Annual Healthcare Conference
8. Trubion Pharmaceuticals Provides Announcement Dates for Third-Quarter and Nine Months Earnings Conference Call
9. NeoStem Signs Definitive Agreement to Acquire Controlling Interest in a Leading Chinese Pharmaceutical Company
10. MiddleBrook Pharmaceuticals Retains National Account Firm VCG & Associates
11. Pacira Pharmaceuticals Leverages TalentManager(R) from Salary.Com(TM) to Integrate Compensation and Performance Management Processes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2014)... Hamilton, ON (September 22, 2014) McMaster scientists have ... a new class of antibiotics. , Although dozens ... looked at how a certain part of bacteria are ... stopping it. , The discovery is important as ... is making the cures for infections ineffective. The World ...
(Date:9/22/2014)... 2014 This Flash Report is a ... needs for the Prostate Cancer market. , Download the ... strategies for any launching Prostate Cancer product:, ... an increasingly crowded market , Understanding stakeholder ... identifying community-based thought leaders and stakeholders ,Download the ...
(Date:9/22/2014)... researchers have published a pilot study showing the ... people with multiple sclerosis (MS). Improvements were ... and pain. "Development and effectiveness of a ... Description and outcomes" was epublished ahead of print ... of MS Care (doi: 10.7224/1537-2073.2013-045). The authors ...
(Date:9/22/2014)... New York (PRWEB) September 22, 2014 ... with the use of power morcellators ( http://www.gynecaremorcellatorlawsuit.com/ ... notes a new report detailing the continued use ... from federal regulators that specifically discouraged these procedures. ... believe that the potential cancer risks associated with ...
(Date:9/22/2014)... HealthDay Reporter MONDAY, Sept. ... wonders: What can I do to help ensure a healthy ... prescribed may play a role in reducing the risk of ... researchers found that mothers of children with autism were significantly ... pregnancy than those whose children seem to be developing normally. ...
Breaking Medicine News(10 mins):Health News:Download HeartBeat Experts White Paper: Stakeholder Management for new Prostate Cancer Products 2Health News:Power Morcellator News: Bernstein Liebhard LLP Notes New Report Detailing Continued Use of Uterine Morcellation Despite FDA Warning 2Health News:Power Morcellator News: Bernstein Liebhard LLP Notes New Report Detailing Continued Use of Uterine Morcellation Despite FDA Warning 3Health News:Power Morcellator News: Bernstein Liebhard LLP Notes New Report Detailing Continued Use of Uterine Morcellation Despite FDA Warning 4Health News:Could Low Iron Intake During Pregnancy Raise Autism Risk? 2Health News:Could Low Iron Intake During Pregnancy Raise Autism Risk? 3
... training program designed to increase empathy with their ... their interactions with the residents. This contrasts with ... drops during medical school and residency training. The ... (MGH) researchers will appear in the Journal ...
... immunise against serious pneumococcal disease does not offer full ... University of Gothenburg, Sweden, finding that the number of ... Each year an estimated 1 million children worldwide ... are those in poor countries, but pneumococcal bacteria cause ...
... be an indicator of whether a person is high-risk for ... of Colorado School of Medicine, shows people with blue eyes ... to scientists, that people with brown eyes may be less ... in which pigment loss results in irregular white patches of ...
... , FRIDAY, May 4 (HealthDay News) -- Thermography -- a ... for mammography -- is an unreliable cancer screen, according to ... thermography missed about 50 percent of cancers and delivered too ... Bryn Mawr Hospital in Pennsylvania. The radiation-free screening method ...
... News) -- Obese drivers are less likely than normal-weight drivers ... Researchers from the University at Buffalo, in New York, analyzed ... normal-weight drivers were 67 percent more likely to wear a ... a body-mass index (BMI) of 40 or higher is considered ...
... -- Patients with mental health emergencies wait an average of ... emergency departments, and those who are older, uninsured or intoxicated ... with psychiatric emergencies wait about 42 percent longer in the ... online May 1 in the Annals of Emergency Medicine ...
Cached Medicine News:Health News:Brief training program improves resident physicians' empathy with patients 2Health News:Brief training program improves resident physicians' empathy with patients 3Health News:Pneumococcal disease: More cases but fewer deaths 2Health News:Eye color may indicate risk for serious skin conditions 2Health News:Mammograms Beat Thermography for Breast Cancer Detection: Study 2Health News:Mammograms Beat Thermography for Breast Cancer Detection: Study 3Health News:Obese Drivers Less Likely to Buckle Up: Study 2Health News:Psychiatric Patients Often Wait Nearly 12 Hours in ER 2
(Date:9/22/2014)... , Sept. 22, 2014  Aethlon Medical, ... therapeutic devices to address infectious disease, cancer and ... Advanced Research Projects Agency (DARPA) has informed the ... to proceed with year four of a five-year ... on September 30, 2011 under DARPA,s Dialysis-Like Therapeutics ...
(Date:9/22/2014)... Sept. 22, 2014  Neuralstem, Inc. (NYSE MKT: CUR) announced ... at Emory University, presented long-term follow up data on ... cells in the treatment of amyotrophic lateral sclerosis (ALS ... occurred at the Annual Symposium on ALS of the ... on Friday, and was not open to the public, ...
(Date:9/22/2014)... Pa. , Sept. 22, 2014  Olympus, ... innovative solutions for medical and surgical procedures, among ... a deal with Munich -based ... Kick ® Navigation. This agreement applies to ... for cross-disciplinary U.S. sales and all distribution outside ...
Breaking Medicine Technology:Aethlon Medical Receives Notice of DARPA Contract Renewal 2Aethlon Medical Receives Notice of DARPA Contract Renewal 3Aethlon Medical Receives Notice of DARPA Contract Renewal 4Neuralstem ALS Investigator Presents Long-Term Follow Up Phase I Data 2Neuralstem ALS Investigator Presents Long-Term Follow Up Phase I Data 3Neuralstem ALS Investigator Presents Long-Term Follow Up Phase I Data 4Olympus Partners with Brainlab as Exclusive Distributor for ENT Products in U.S. Market 2Olympus Partners with Brainlab as Exclusive Distributor for ENT Products in U.S. Market 3Olympus Partners with Brainlab as Exclusive Distributor for ENT Products in U.S. Market 4
The Optima III 45 cm line of laparoscopic hand instruments is ideal for operative laparoscopic/endoscopic procedures or when a longer instrument is needed....
The Optima III 45 cm line of laparoscopic hand instruments is ideal for operative laparoscopic/endoscopic procedures or when a longer instrument is needed....
The Optima III line of laparoscopic hand instruments provides a well-crafted set of instruments designed for strength and durability....
The Optima III line of laparoscopic hand instruments provides a well-crafted set of instruments designed for strength and durability....
Medicine Products: